Multiple sclerosis and related disorders · 2026
Real-world cost of disease-modifying treatments administered by intravenous infusion in relapsing-remitting multiple sclerosis patients from Argentina.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Silva Berenice A, Federico María B, Lázaro Luciana, Casas Magdalena, Burgos Marcos, Maniella Carolina, Tavolini Darío, López Pablo, Carnero Contentti Edgar, Tkachuk Verónica, Vrech Carlos, Zárate María Agustina, Rojas Juan I, Alonso Ricardo, Elgart Jorge
Аннотация
BACKGROUND: Published real-world evidence on the direct and indirect costs associated with infused disease-modifying treatments (IV-DMTs) for relapsing-remitting multiple sclerosis (RRMS) remains scarce in Argentina and Latin America.
OBJECTIVE: To estimate first-year real-world direct and indirect costs of IV-DMTs [ocrelizumab (OCR), alemtuzumab (ATZ) and natalizumab (NTZ)] in RRMS patients in Argentina.
METHODS: We conducted a non-interventional study of adult RRMS patients who initiated IV-DMTs between August 2018 and August 2020. Resource use and costs were collected via an ad hoc questionnaire. Direct and indirect costs were calculated using unit costs in Argentine pesos (December 2022) and converted to US dollars (1 USD = AR$172.9).
RESULTS: A total of 125 patients were analysed (mean age 35.9 years; disease duration 8.9 years; EDSS 2.0). The most frequently used IV-DMTs were NTZ (51.2%), OCR (33.6%), and ATZ (15.2%). Total annual costs averaged USD 62,831 ± 14,813 per patient, with the DMT itself accounting for 85% of total costs. By treatment, first-year costs were USD 85,293 for ATZ; USD 56,140 for NTZ; and USD 62,867 for OCR. Costs did not differ by sex or EDSS.
CONCLUSION: First-year IV-DMT costs averaged USD 62,831, approximately 4.5 times the Argentine GDP per capita, highlighting the substantial economic burden of these treatments in Argentina.
OBJECTIVE: To estimate first-year real-world direct and indirect costs of IV-DMTs [ocrelizumab (OCR), alemtuzumab (ATZ) and natalizumab (NTZ)] in RRMS patients in Argentina.
METHODS: We conducted a non-interventional study of adult RRMS patients who initiated IV-DMTs between August 2018 and August 2020. Resource use and costs were collected via an ad hoc questionnaire. Direct and indirect costs were calculated using unit costs in Argentine pesos (December 2022) and converted to US dollars (1 USD = AR$172.9).
RESULTS: A total of 125 patients were analysed (mean age 35.9 years; disease duration 8.9 years; EDSS 2.0). The most frequently used IV-DMTs were NTZ (51.2%), OCR (33.6%), and ATZ (15.2%). Total annual costs averaged USD 62,831 ± 14,813 per patient, with the DMT itself accounting for 85% of total costs. By treatment, first-year costs were USD 85,293 for ATZ; USD 56,140 for NTZ; and USD 62,867 for OCR. Costs did not differ by sex or EDSS.
CONCLUSION: First-year IV-DMT costs averaged USD 62,831, approximately 4.5 times the Argentine GDP per capita, highlighting the substantial economic burden of these treatments in Argentina.